A secondary analysis of a metformin-versus-insulin gestational diabetes trial found cord serum lipids associated with offspring beta-cell function at age nine. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
In children aged 2-6 years with type 1 diabetes, the MiniMed 780G in auto mode improved time in range and HbA1c over manual mode with suspend-before-low, meeting non-inferiority with superiority. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.
A 13-week randomised trial found automated insulin delivery sharply lowered HbA1c in youth with type 1 diabetes but objectively reduced sleep efficiency and increased night-time wakefulness. PICO summary and expert commentary.
A 6-month randomised trial in older adults with type 2 diabetes found home telemedicine plus Health Belief Model education cut HbA1c by 0.42% more than usual care. PICO summary and expert commentary.
In 28 AID-naive adults with type 1 diabetes, a tubeless open-source hybrid loop (AndroidAPS) raised time in range to 75.6 percent versus 60.4 percent on sensor-augmented pump therapy without added hypoglycaemia. PICO summary and expert commentary.
A randomized crossover trial found the cardiac output response to 3-hydroxybutyrate was blunted by roughly 80% in type 1 diabetes, with no gain in systolic function and reduced ventricular work efficiency. PICO summary and expert commentary.